CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy

Diana M. Escolar; Gunnar Buyse; Erik Henricson; Robert Leshner; Julaine Florence; Jill Mayhew; Carolina Tesi-Rocha; Ksenija Gorni; Livia Pasquali; Kantilal M. Patel; Robert McCarter; Jennifer Huang; Thomas Mayhew; Tulio Bertorini; Jose Carlo; Anne M. Connolly; Paula R. Clemens; Nathalie Goemans; Susan T. Iannaccone; Masanori Igarashi; Yoram Nevo; Alan Pestronk; S. H. Subramony; V. V. Vedanarayanan; Henry Wessel

doi:10.1002/ana.20523

CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy

Diana M. Escolar, Gunnar Buyse, Erik Henricson, Robert Leshner, Julaine Florence, Jill Mayhew, Carolina Tesi-Rocha, Ksenija Gorni, Livia Pasquali, Kantilal M. Patel, Robert McCarter, Jennifer Huang, Thomas Mayhew, Tulio Bertorini, Jose Carlo, Anne M. Connolly, Paula R. Clemens, Nathalie Goemans, Susan T. Iannaccone, Masanori IgarashiYoram Nevo, Alan Pestronk, S. H. Subramony, V. V. Vedanarayanan, Henry Wessel

Research output: Contribution to journal › Article › peer-review

73 Scopus citations

Abstract

We tested the efficacy and safety of glutamine (0.6gm/kg/day) and creatine (5gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, doubleblind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.

Original language	English (US)
Pages (from-to)	151-155
Number of pages	5
Journal	Annals of neurology
Volume	58
Issue number	1
DOIs	https://doi.org/10.1002/ana.20523
State	Published - Jul 2005
Externally published	Yes

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/ana.20523

Cite this

Escolar, D. M., Buyse, G., Henricson, E., Leshner, R., Florence, J., Mayhew, J., Tesi-Rocha, C., Gorni, K., Pasquali, L., Patel, K. M., McCarter, R., Huang, J., Mayhew, T., Bertorini, T., Carlo, J., Connolly, A. M., Clemens, P. R., Goemans, N., Iannaccone, S. T., ... Wessel, H. (2005). CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Annals of neurology, 58(1), 151-155. https://doi.org/10.1002/ana.20523

Escolar, DM, Buyse, G, Henricson, E, Leshner, R, Florence, J, Mayhew, J, Tesi-Rocha, C, Gorni, K, Pasquali, L, Patel, KM, McCarter, R, Huang, J, Mayhew, T, Bertorini, T, Carlo, J, Connolly, AM, Clemens, PR, Goemans, N, Iannaccone, ST, Igarashi, M, Nevo, Y, Pestronk, A, Subramony, SH, Vedanarayanan, VV & Wessel, H 2005, 'CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy', Annals of neurology, vol. 58, no. 1, pp. 151-155. https://doi.org/10.1002/ana.20523

@article{5d154634c5fb48838058f30d2b4b5115,

title = "CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy",

abstract = "We tested the efficacy and safety of glutamine (0.6gm/kg/day) and creatine (5gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, doubleblind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.",

author = "Escolar, {Diana M.} and Gunnar Buyse and Erik Henricson and Robert Leshner and Julaine Florence and Jill Mayhew and Carolina Tesi-Rocha and Ksenija Gorni and Livia Pasquali and Patel, {Kantilal M.} and Robert McCarter and Jennifer Huang and Thomas Mayhew and Tulio Bertorini and Jose Carlo and Connolly, {Anne M.} and Clemens, {Paula R.} and Nathalie Goemans and Iannaccone, {Susan T.} and Masanori Igarashi and Yoram Nevo and Alan Pestronk and Subramony, {S. H.} and Vedanarayanan, {V. V.} and Henry Wessel",

year = "2005",

month = jul,

doi = "10.1002/ana.20523",

language = "English (US)",

volume = "58",

pages = "151--155",

journal = "Annals of neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy

AU - Escolar, Diana M.

AU - Buyse, Gunnar

AU - Henricson, Erik

AU - Leshner, Robert

AU - Florence, Julaine

AU - Mayhew, Jill

AU - Tesi-Rocha, Carolina

AU - Gorni, Ksenija

AU - Pasquali, Livia

AU - Patel, Kantilal M.

AU - McCarter, Robert

AU - Huang, Jennifer

AU - Mayhew, Thomas

AU - Bertorini, Tulio

AU - Carlo, Jose

AU - Connolly, Anne M.

AU - Clemens, Paula R.

AU - Goemans, Nathalie

AU - Iannaccone, Susan T.

AU - Igarashi, Masanori

AU - Nevo, Yoram

AU - Pestronk, Alan

AU - Subramony, S. H.

AU - Vedanarayanan, V. V.

AU - Wessel, Henry

PY - 2005/7

Y1 - 2005/7

N2 - We tested the efficacy and safety of glutamine (0.6gm/kg/day) and creatine (5gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, doubleblind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.

AB - We tested the efficacy and safety of glutamine (0.6gm/kg/day) and creatine (5gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, doubleblind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=21844474016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21844474016&partnerID=8YFLogxK

U2 - 10.1002/ana.20523

DO - 10.1002/ana.20523

M3 - Article

C2 - 15984021

AN - SCOPUS:21844474016

SN - 0364-5134

VL - 58

SP - 151

EP - 155

JO - Annals of neurology

JF - Annals of neurology

IS - 1

ER -

CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this